Manganese Capture‐and‐Release Vesicles for Cancer Immunotherapy
Advanced Materials · 2026
DOI: 10.1002/adma.74498 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Materials, 2026. Verfasst von Gengqi Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Frontiers Science Center for Synthetic Biology (Ministry…. Hauptthemen laut MEDLINE: Manganese, Immunotherapy, Neoplasms. Die Arbeit nennt 61 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Manganese activates the stimulator of interferon genes (STING) pathway, and its sequestration by the TssS micropeptide of Yersinia pseudotuberculosis is an immune evasion tactic. Inspired by this, we developed MnCARS , Mn CA pture‐and‐ R elease vesicles with S TING adjuvant MSA‐2, which capture endogenous manganese ions and release them in cancer cells. Constructed from engineered E. Coli outer membrane vesicles (OMVs), the system integrates surface‐displayed TssS to accumulate endogenous Mn 2+ , with a von Hippel–Lindau (VHL) PROTAC degradation motif that triggers Mn 2+ release via ubiquitin‐proteasome‐mediated cleavage of TssS upon cellular uptake, rather than non‐specific degradation by lysosomal proteases. The surface‐anchored STING agonist MSA‐2 synergizes with the released Mn 2+ to potentiate cGAS‐STING activation and reverse the immunosuppressive tumor microenvironment. In vitro, MnCARS enriched Mn 2+ and triggered dendritic cell maturation. In vivo, they elicited antitumor immunity, inhibiting the growth of subcutaneous CT26 tumors and improving survival in an orthotopic pancreatic cancer model. To demonstrate platform versatility and enable tumor targeting, a tumor‐tropic P eptide was inserted in CAR instead of MSA‐2, yielding MnCARP that enables monitoring Mn 2+ release and STING activation with contrast‐enhanced magnetic resonance imaging (MRI). Overall, MnCARs represent a versatile biological nanoplatform to redirect endogenous metal ions for cancer therapy with inherent imaging capabilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Synthetic Biology and Biomanufacturing, State Key Laboratory of Synthetic Biology, Frontiers Science Center for Synthetic Biology (Ministry of Education), Tianjin University, Tianjin, P. R. China.
- Department of Chemical and Biological Engineering, University at Buffalo, The State University of New York, Buffalo, New York, USA.
- Department of Biomedical Engineering, University at Buffalo, The State University of New York, Buffalo, New York, USA.
ORCID-Profile: He Ren, Chong Cheng, Jonathan F Lovell, Lin Zhang, Yumiao Zhang
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Program
- China Postdoctoral Science Foundation
- National Key Research and Development Program of China
Zitieren
APA
Liu, G., Hu, F., Ren, H., Dong, W., Li, Z., Cheng, C., Lovell, J. F., Zhang, L., & Zhang, Y. (2026). Manganese Capture‐and‐Release Vesicles for Cancer Immunotherapy. Advanced Materials. https://doi.org/10.1002/adma.74498
Vancouver
Liu G, Hu F, Ren H, Dong W, Li Z, Cheng C, et al. Manganese Capture‐and‐Release Vesicles for Cancer Immunotherapy. Advanced Materials. 2026. doi:10.1002/adma.74498
BibTeX
@article{Liu2026,
author = {Liu, Gengqi and Hu, Fuzhen and Ren, He and Dong, Wenhao and Li, Zekun and Cheng, Chong and Lovell, Jonathan F and Zhang, Lin and Zhang, Yumiao},
title = {Manganese Capture‐and‐Release Vesicles for Cancer Immunotherapy},
journal = {Advanced Materials},
year = {2026},
doi = {10.1002/adma.74498}
}
EUVIMED